P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC (2023)
- Authors:
- USP affiliated authors: STEFANO, JOSÉ TADEU - FM ; CARRILHO, FLAIR JOSÉ - FM ; ALVES, VENANCIO AVANCINI FERREIRA - FM ; COGLIATI, BRUNO - FMVZ ; OLIVEIRA, CLAUDIA PINTO MARQUES SOUZA DE - FM ; REIS, JOAO PEDRO NASSAR - FMVZ ; UMETA, PEDRO FUKUI - FM
- Unidades: FM; FMVZ
- DOI: 10.1007/s10735-023-10142-9
- Subjects: CARCINOMA HEPATOCELULAR; HEPATITE; INIBIDORES DE ENZIMAS; BIOMARCADORES
- Keywords: HCC; NASH; NAFLD; Sorafenib; VEGF; p53
- Agências de fomento:
- Language: Inglês
- Imprenta:
- Source:
- Título: Journal of Molecular Histology
- ISSN: 1567-2379
- Volume/Número/Paginação/Ano: v. 54, p. 473-488, 2023
- Este periódico é de assinatura
- Este artigo NÃO é de acesso aberto
- Cor do Acesso Aberto: closed
-
ABNT
REIS, João Pedro Nassar et al. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC. Journal of Molecular Histology, v. 54, p. 473-488, 2023Tradução . . Disponível em: https://doi.org/10.1007/s10735-023-10142-9. Acesso em: 03 nov. 2024. -
APA
Reis, J. P. N., Umeta, P. F., Stefano, J. T., Longatto Filho, A., Carrilho, F. J., Alves, V. A. F., et al. (2023). P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC. Journal of Molecular Histology, 54, 473-488. doi:10.1007/s10735-023-10142-9 -
NLM
Reis JPN, Umeta PF, Stefano JT, Longatto Filho A, Carrilho FJ, Alves VAF, Cogliati B, Oliveira CPMS de. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC [Internet]. Journal of Molecular Histology. 2023 ; 54 473-488.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1007/s10735-023-10142-9 -
Vancouver
Reis JPN, Umeta PF, Stefano JT, Longatto Filho A, Carrilho FJ, Alves VAF, Cogliati B, Oliveira CPMS de. P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH‑related HCC [Internet]. Journal of Molecular Histology. 2023 ; 54 473-488.[citado 2024 nov. 03 ] Available from: https://doi.org/10.1007/s10735-023-10142-9 - Hepatocellular carcinoma (HCC) in patients with Non-Alcoholic Fatty Liver Disease (NAFLD): screening, treatment and survival analysis in a Brazilian series
- Combination of N-acetylcysteine and metformin improves histological steatosis and fibrosis in patients with non-alcoholic steatohepatitis
- Experimental models of liver fibrosis
- Strategies, models and biomarkers in experimental non-alcoholic fatty liver disease research
- The combination of probiotics and prebiotics supplementation improves lipid metabolism, NAFLD and obesity in ob/ob mice
- P53 and VEGF are promising biomarkers for sorafenib efficacy in an experimental model of NASH-related HCC
- S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
- Survivin expression patterns could reflect different roles in hepatocarcinogenesis, especially in non-alcoholic fatty liver disease-related hepatocellular carcinoma [Carta]
- Accuracy of transient elastography-FibroScan®, acoustic radiation force impulse (ARFI) imaging, the enhanced liver fibrosis (ELF) test, APRI, and the FIB-4 index compared with liver biopsy in patients with chronic hepatitis C
- Omega-3 polyunsaturated fatty acids in treating non-alcoholic steatohepatitis: a randomized, double-blind, placebo-controlled trial
Informações sobre o DOI: 10.1007/s10735-023-10142-9 (Fonte: oaDOI API)
How to cite
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
